CAMBRIDGE, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
H.C. Wainwright Cell Therapy Virtual Conference
Fireside Chat recording available on Tuesday, February 28, 2023 at 7:00 am ET
Inaugural Mizuho Oncology Therapeutics Summit
Panel: Developing & Commercializing Cell Therapy
Date: Monday, March 13, 2023 at 8:00 am
Location: Cadillac Hotel & Beach Club, Miami, FL
Oppenheimer 33rd Annual Virtual Healthcare Conference
Presentation: Monday, March 13, 2023 at 1:20 pm ET
Barclays Global Healthcare Conference
Fireside Chat: Wednesday, March 15, 2023 at 2:05 pm ET
Location: Loews Miami Beach Hotel, Miami, FL
A live webcast and archived replay of the presentation and fireside chats will be available on the investors section of our website, linked here: https://ir.vorbio.com/events-presentations/
About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Contact:
Media & Investors
Sarah Spencer
+1 857-242-6076
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.30 |
| Daily Change: | -0.04 -2.99 |
| Daily Volume: | 537,487 |
| Market Cap: | US$161.900M |
January 08, 2025 December 27, 2024 September 05, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
